177Lu-DOTA-Miltuximab / GlyTherix - LARVOL DELTA

Nusano and GlyTherix Announce Lutetium-177 Supply Agreement (GlobeNewswire) - "Nusano...and GlyTherix Ltd...announced a supply agreement for non-carrier-added lutetium-177 (Lu-177). The agreement also provides GlyTherix access to Nusano’s future actinium-225 (Ac-225) production, currently scheduled to begin in 2026, and planned future production of zirconium-89 (Zr-89), lead-212 (Pb-212) and terbium-161 (Tb-161)....GlyTherix plans to use 177Lu-DOTAMiltuximab in its planned Australian Phase Ib in 2025, followed by US Phase II trials in 2026."

Commercial • New P1 trial • New P2 trial • Oncology • Solid Tumor

GlyTherix to Partner with SHINE Technologies for Advancing Targeted Radiotherapy in Aggressive Cancers (PRNewswire) - "GlyTherix Ltd...is pleased to announce a new global clinical supply agreement with Wisconsin-based SHINE Technologies, a pioneer in next-generation fusion-based technology and North America's largest producer of non-carrier added lutetium-177 (n.c.a. Lu-177) chloride. SHINE will supply its n.c.a. Lu-177 chloride, Ilumira, for use in GlyTherix's clinical trials focused on innovative treatments for aggressive and invasive cancers....Their 177Lu-DOTA-Miltuximab will enter Phase Ib trials in early 2025. GlyTherix will use 177Lu-DOTA-Miltuximab targeting tumors expressing Glypican-1 in its planned Australian Phase Ib therapeutic dose escalation trial scheduled to commence early 2025."

Commercial • New P1 trial • Oncology • Solid Tumor